GSK1265744
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for GSK1265744, covering 2017-12-15 to 2020-01-30. Get the full timeline:
Most recent: Clinical Trial Update: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine [Phase 2]